Caseware UK (AP4) 2023.0.135 2023.0.135 2024-06-30trueProvide of community opthalmology servicestruetruetruetruefalse3592023-07-01false519true 07296068 2023-07-01 2024-06-30 07296068 2022-07-01 2023-06-30 07296068 2024-06-30 07296068 2023-06-30 07296068 2022-07-01 07296068 1 2023-07-01 2024-06-30 07296068 1 2022-07-01 2023-06-30 07296068 d:Director1 2023-07-01 2024-06-30 07296068 d:RegisteredOffice 2023-07-01 2024-06-30 07296068 e:Buildings 2023-07-01 2024-06-30 07296068 e:Buildings e:LongLeaseholdAssets 2023-07-01 2024-06-30 07296068 e:Buildings e:LongLeaseholdAssets 2024-06-30 07296068 e:Buildings e:LongLeaseholdAssets 2023-06-30 07296068 e:PlantMachinery 2023-07-01 2024-06-30 07296068 e:PlantMachinery 2024-06-30 07296068 e:PlantMachinery 2023-06-30 07296068 e:PlantMachinery e:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 07296068 e:MotorVehicles 2023-07-01 2024-06-30 07296068 e:MotorVehicles 2024-06-30 07296068 e:MotorVehicles 2023-06-30 07296068 e:MotorVehicles e:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 07296068 e:FurnitureFittings 2023-07-01 2024-06-30 07296068 e:FurnitureFittings 2024-06-30 07296068 e:FurnitureFittings 2023-06-30 07296068 e:FurnitureFittings e:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 07296068 e:ComputerEquipment 2023-07-01 2024-06-30 07296068 e:ComputerEquipment 2024-06-30 07296068 e:ComputerEquipment 2023-06-30 07296068 e:ComputerEquipment e:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 07296068 e:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 07296068 e:CurrentFinancialInstruments 2024-06-30 07296068 e:CurrentFinancialInstruments 2023-06-30 07296068 e:Non-currentFinancialInstruments 2023-07-01 2024-06-30 07296068 e:Non-currentFinancialInstruments 2024-06-30 07296068 e:Non-currentFinancialInstruments 2023-06-30 07296068 e:ReportableOperatingSegment1 2023-07-01 2024-06-30 07296068 e:ReportableOperatingSegment1 2022-07-01 2023-06-30 07296068 e:UKTax 2023-07-01 2024-06-30 07296068 e:UKTax 2022-07-01 2023-06-30 07296068 e:ShareCapital 2023-07-01 2024-06-30 07296068 e:ShareCapital 2024-06-30 07296068 e:ShareCapital 2022-07-01 2023-06-30 07296068 e:ShareCapital 2023-06-30 07296068 e:ShareCapital 2022-07-01 07296068 e:RetainedEarningsAccumulatedLosses 2023-07-01 2024-06-30 07296068 e:RetainedEarningsAccumulatedLosses 2024-06-30 07296068 e:RetainedEarningsAccumulatedLosses 2022-07-01 2023-06-30 07296068 e:RetainedEarningsAccumulatedLosses 2023-06-30 07296068 e:RetainedEarningsAccumulatedLosses 2022-07-01 07296068 e:AcceleratedTaxDepreciationDeferredTax 2024-06-30 07296068 e:AcceleratedTaxDepreciationDeferredTax 2023-06-30 07296068 e:TaxLossesCarry-forwardsDeferredTax 2024-06-30 07296068 e:TaxLossesCarry-forwardsDeferredTax 2023-06-30 07296068 e:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2023-07-01 2024-06-30 07296068 e:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2024-06-30 07296068 e:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2023-06-30 07296068 d:OrdinaryShareClass1 2023-07-01 2024-06-30 07296068 d:OrdinaryShareClass1 2024-06-30 07296068 d:OrdinaryShareClass1 2023-06-30 07296068 d:OrdinaryShareClass2 2023-07-01 2024-06-30 07296068 d:OrdinaryShareClass2 2024-06-30 07296068 d:OrdinaryShareClass2 2023-06-30 07296068 d:OrdinaryShareClass3 2023-07-01 2024-06-30 07296068 d:OrdinaryShareClass3 2024-06-30 07296068 d:OrdinaryShareClass3 2023-06-30 07296068 d:FRS102 2023-07-01 2024-06-30 07296068 d:Audited 2023-07-01 2024-06-30 07296068 d:FullAccounts 2023-07-01 2024-06-30 07296068 d:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 07296068 e:Subsidiary1 2023-07-01 2024-06-30 07296068 e:Subsidiary1 1 2023-07-01 2024-06-30 07296068 e:WithinOneYear 2024-06-30 07296068 e:WithinOneYear 2023-06-30 07296068 e:BetweenOneFiveYears 2024-06-30 07296068 e:BetweenOneFiveYears 2023-06-30 07296068 e:MoreThanFiveYears 2024-06-30 07296068 e:MoreThanFiveYears 2023-06-30 07296068 e:HirePurchaseContracts e:WithinOneYear 2024-06-30 07296068 e:HirePurchaseContracts e:WithinOneYear 2023-06-30 07296068 e:HirePurchaseContracts e:BetweenOneFiveYears 2024-06-30 07296068 e:HirePurchaseContracts e:BetweenOneFiveYears 2023-06-30 07296068 2 2023-07-01 2024-06-30 07296068 6 2023-07-01 2024-06-30 07296068 e:PlantMachinery e:LeasedAssetsHeldAsLessee 2024-06-30 07296068 e:PlantMachinery e:LeasedAssetsHeldAsLessee 2023-06-30 07296068 f:PoundSterling 2023-07-01 2024-06-30 iso4217:GBP xbrli:shares xbrli:pure



















Community Health and Eyecare Limited

Registered number: 07296068
Annual report and financial statements
For the year ended 30 June 2024

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
COMPANY INFORMATION


Director
I Rahman 




Registered number
07296068



Registered office
1-6 Star Building
Caxton Road

Fulwood

Preston

PR2 9BS




Independent auditor
Forvis Mazars LLP
Chartered Accountants & Statutory Auditor

One St. Peter's Square

Manchester

M2 3DE





 
COMMUNITY HEALTH AND EYECARE LIMITED
 

CONTENTS



Page
Strategic Report
 
1 - 5
Director's Report
 
6 - 9
Independent Auditor's Report
 
10 - 13
Statement of Comprehensive Income
 
14
Statement of Financial Position
 
15 - 16
Statement of Changes in Equity
 
17
Notes to the Financial Statements
 
18 - 33


 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
STRATEGIC REPORT
FOR THE YEAR ENDED 30 JUNE 2024

Introduction
 
The directors present the Company strategic report for the year ended 30 June 2024.

Business review
 
The Company is one of the UK’s leading providers of community-based healthcare services, specialising in Ophthalmology and Gastroenterology services across the UK.
Our team has built a reputation of patient focused care, ensuring we are responsive and considerate to the needs of our patients. As a leading independent healthcare organisation delivering predominantly NHS care, and some private services, our growing reputation is underpinned by our dedicated medical and nursing teams, with our people and operations teams at the centre of what we do.
The Company operates from over one hundred locations nationwide. Our increasing footprint is supported by NHS community contracts in dedicated outpatient facilities and CHEC community hospitals. As of 30th June 2024, CHEC has 27 community hospitals, with a further pipeline of 11 sites in 2024/25.  
The directors are extremely pleased with the underlying performance of the Company in the period, and would like to thank the Company’s employees for their hard work and commitment in delivering outstanding patient care.
The Company aims to strategically grow the business through acquisitions, organic growth through green field sites and contract awards through normal procurement methods. The growth strategy will ensure a multi-faceted approach driving business growth and stability within the Ophthalmology, Gastroenterology, Dermatology and ENT market space.  
The Company has continued its growth strategy by maximising current contracts, winning new commissioned contracts and expanding our green field hospital base from 18 in 2023 to 27 in 2024. 

Principal risks and uncertainties
 
In determining whether the Company's accounts can be prepared on a going concern basis, the directors considered the Company’s business activities together with the factors likely to affect its future development, performance, its financial position including cash flows, liquidity position, borrowing facilities and the risks and uncertainties in relation to its business activities. The directors regularly review these factors to ensure that any risks are recognised and managed effectively.
The principal risks affecting the business are as follows:
Financial
The Company has a number of financial instruments which include cash, trade debtors and trade creditors that arise directly from operations. The main purpose of these financial instruments is to support the Company’s growth and its day-to-day operations. From a daily operational basis, the company seeks to manage financial risk by ensuring sufficient liquidity is available to meet foreseeable needs and to invest cash assets safely and profitably.
 
- 1 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024

The Company’s principal financial assets are cash and trade debtors. The credit risk associated with the cash is limited as the banks have good credit ratings assigned by international credit-rating agencies. The principal credit risk arises from its trade debtors. The risk of non-receipt of monies owed is minimal as the majority of the debtors are from the NHS which is funded by central government.
The Company has significant cash resources and facilities available to manage the future trading performance and any foreseeable changes.
Retaining and recruiting staff
The Company focuses on employing and retaining the highest quality clinical and non-clinical staff, including key management. Retaining these staff is key to continued growth and success of the business. The Company has policies in place to ensure these staff are retained and motivated.
Reputational risk
The Company is focused on both the patients experience and outcomes from their operations and treatments. Maintaining these to the highest of standards is key in ensuring the Company’s reputation and these standards are reviewed monthly by the board. The Company has and continues to invest in the clinical governance structures within the business to ensure that all the best practices are followed, and all accreditations are maintained.
Operational risk
The majority of the Company’s revenues (97%) are through contracts with NHS Integrated Care Boards (ICB's). A reduction in this revenue could have a negative impact on the Company. Contracts are negotiated under local and national tariffs generating the activity performed on behalf of the NHS. The Company is a contracted provider with 31 ICB's securing 17 new commissioned service contracts in 2024. The Company’s national presence contributes to ongoing collaboration with almost all 42 ICB's, with very few excluded from our deliverable services.
Economic impact of global events
UK businesses are currently facing many uncertainties such as the consequences of Brexit, environmental sustainability and geopolitical events such as Ukraine and the Middle East instability. These uncertainties have contributed to an environment where there exists a range of issues and risks, including inflation, rising interest rates, labour shortages, disrupted supply chains and new ways of working.
The directors have carried out an assessment of the potential impact of these uncertainties on the business, including the impact of mitigation measures, and have concluded that the greatest impact on the business is expected to be from the economic ripple effect on the global economy. The directors have taken account of these potential impacts in their going concern assessment. 
Community Health and Eyecare Limited continues to work with its partners to minimise any impacts of these events and maximise the realisation of any opportunities they may provide to the business. 
 
- 2 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024


Financial key performance indicators

The board reviews the Company’s KPI’s at the monthly board meetings as well as on weekly and daily dashboards. These include clinical, operational, and financial measurements.
Our key clinical measurement is patient satisfaction information. The Company obtains information for all our patients after procedures to ensure that the patient received the highest quality care and service. The Company achieved an average patient satisfaction rating of 98.19% (2023: 99.65%), and 99.78% (2023: 99.85%) of patients would recommend the Company’s services to their family and friends.
Management believes the most appropriate financial KPI’s are set out in the table below:


2024
2023

£
£
Turnover
£ 80.0m
£55.3m
Profit before tax
£ 19.2m
£14.2m
Net current assets
£ 17.7m
£14.2m
Net assets
£ 49.8m
£34.3m
Total employed staff
519
359


Director's statement of compliance with duty to promote the success of the Company under section 172
 
The board of directors of Community Health and Eyecare Limited consider that both individually and together that they have acted in the way they consider, in good faith, would be the most likely to promote the success of the Company for the benefit of its members as a whole, and in doing so have regard (amongst other matters set out in s172(1)(a-f) of the Act) to:
a) the likely consequences of any decision in the long term;
b) the interests of the Company’s employees;
c) the need to foster the Company’s business relationships with suppliers, customers and others;
d) the impact of the Company’s operations on the community and the environment;
e) the desirability of the Company maintaining a reputation for high standards of business conduct;
f) the need to act fairly as between members of the Company. 
The following paragraphs summarise how the directors fulfil their duties to promote the success of the Company:
The likely consequences of any decision in the long term
The directors consider the potential impacts of their decisions on the company's long-term objectives and sustainability, as well as on its stakeholders and the community, while also upholding its values and culture. We are a business built on our standards and reputation and would not take a decision which would have a detrimental impact on this, whether in the short term or the long term. We are dedicated to ensuring we maintain our culture whilst achieving our purpose.
 
- 3 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024

The interests of the Company’s employees
The way we are organisationally structured is pivotal to the delivery and success of our business strategy.  We aim to be a value-based employer of choice and demonstrate this through our external accreditations of Investors in People, Great Places to Work (engagement) and Thrive at Work (health and wellbeing).  Our employee value proposition is underpinned by a robust reward and recognition strategy that delivers year-on-year improvements.
The Company ensures fair treatment, equal opportunities and diversity across all levels of the workforce. The Company has robust policies, procedures, reporting, analysis, and proactive measures to ensure individuals are treated with dignity and respect.
We engage regularly with our employees through our organisational structure, to understand their concerns, provide platforms for open dialogue, and encourage innovation and collaboration.
The need to foster the Company’s business relationships with suppliers, customers and others
Building and nurturing relationships with key stakeholders is key to the success of the Company. From hospital management through to our Head office teams, we are dedicated to enhancing positive interactions with our patients, Consultant teams, ICB’s, Optometrists, GPs and other key stakeholder groups. We place great importance on these relationships and are committed to providing high-quality healthcare services to our patients. We do this by increasing our focus on pro-active quality improvements and building on our Clinical Governance structure. 
In March 2024, we achieved JAG accreditation for our Nottingham Hospital, and we aim to replicate this success across all our Endoscopy sites, showcasing our dedication to quality and excellence throughout the Company. By demonstrating quality outcomes to our commissioning bodies, our Commercial, Engagement, and Operational teams can build strong and lasting partnerships that contribute to our long-term success.
The impact of the Company’s operations on the community and the environment
The Company has established Environmental, Social, and Governance (ESG) strategic goals that have been approved by the board, supported by a cross-functional working group dedicated to driving improvements. To enhance and align our ESG strategy with our three-year plan, we have engaged ESG consultants to assist in implementing our initiatives in FY25. We take pride in being part of both local and broader communities and strive to prioritise Planet, People, Leadership, and Patients in all our endeavours.
The desirability of the Company maintaining a reputation for high standards of business conduct
Our brand and reputation are invaluable assets to the Company, and the directors are committed to upholding high ethical standards across all business practices. The employee recruitment and onboarding experience is paramount to the success of delivering our people agenda. We continually improve the development of our people through a range of learning and development interventions to strengthen our ability to deliver.
As a Company we promote a culture of transparency, integrity and accountability across all business activities.
As a Company we are focused and passionate about ethical sourcing, sustainability initiatives, and social responsibility. We have a cross functional working party who collaborate with an external partner to drive year on year improvements in this arena.
 
- 4 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024

The need to act fairly between members of the Company
The Company is committed to acting with integrity and courtesy in all of its business relationships, ensuring that the interests of all members and stakeholders are considered when making decisions for the overall good of the Company.
Statement of Corporate Governance Arrangements
As a board of directors, we are committed to behaving responsibly and in collaboration with management. We ensure that we operate the business in a responsible manner, with high standards of business conduct and corporate governance appropriate to our size and complexity.

Future developments

The directors believe the Company’s future prospects to be good. The Company at the date of this report operates from 27 surgical centres, with more planned in the current financial year. The high level of capital investment in these sites, and our investment in hiring and training highly skilled staff, reflects the Company's ambitions going forward.


This report was approved by the board on 31 October 2024 and signed on its behalf.



I Rahman
Director

- 5 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
DIRECTOR'S REPORT
FOR THE YEAR ENDED 30 JUNE 2024

The director presents his report and the financial statements for the year ended 30 June 2024.

Director's responsibilities statement

The director is responsible for preparing the Strategic Report, the Director's Report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the director is required to:


select suitable accounting policies for the Company's financial statements and then apply them consistently;

make judgments and accounting estimates that are reasonable and prudent;

state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable him to ensure that the financial statements comply with the Companies Act 2006He is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Results and dividends

The profit for the year, after taxation, amounted to £15,491,695 (2023 - £11,903,525).

No ordinary dividends were paid (2023: £Nil). The director does not recommend payment of a final dividend.

Director

The director who served during the year was:

I Rahman 

- 6 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
DIRECTOR'S REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024

Going concern

As at 30 June 2024, the Company had net assets of £49.8m (2023: £34.3m) including a bank cash balance of £3.1m (2023: £1.7m). In determining whether the Company’s accounts can be prepared on a going concern basis, the director considers the Company’s business activities together with factors likely to affect future development, performance, it’s financial position including cash flows, liquidity position, borrowing facilities and risks and uncertainties relating to its business activities.
This includes the director regularly reviewing these factors, and the performance and financial position of the wider group to ensure that any risks are recognised and managed effectively.
After considering all these factors the directors have a reasonable expectation that the Company, and wider Group, have adequate resources to continue in operation and manage the risks for the foreseeable future.  Accordingly, the director decided to adopt the going concern basis in the preparation of the annual financial statements.
Greenhouse gas emissions, energy consumption and energy efficiency action
The Company understands that continually improving our environmental performance should be at the forefront of our business. It understands the impact of rising temperatures, extreme weather and the increased pressures climate change is and will have on the NHS. Our carbon reduction plan ensures that the Company is proactively managing and minimising its environmental impact through scientific data reporting. The Company’s carbon reduction plan aligns with the NHS Green Plan.


Measurement

2024
2023




Annual energy consumption used to calculate emissions (kWh)

3,357,000
959,308




Emissions from combustion of gas (Scope 1)

2.10
0.00




Emissions from combustion of fuel for transport purposes (Scope 1)
Total (tCO2e)
122.5
126.0

CO2 (tonnes)
121.3
198.6

CH4 (tonnes)
0
0

N2O (tonnes)
1.2
1.0
Emissions from purchased electricity (Scope 2, location-based)
Total (tCO2e)
443.1
198.6

CO2 (tonnes)
438.5
196.6

CH4 (tonnes)
1.9
0.9

NO2 (tonnes)
2.6
1.2
Emissions from business travel rental cars or employee owned



vehicles where company is responsible for purchasing the fuel (Scope 3)
Total (tCO2e)
169.8
103.4

CO2 (tonnes)
168.1
102.6

CH4 (tonnes)
0
0.1

N2O (tonnes)
1.7
0.6
Direct CO2 emissions from Biogenic combustion

0.0
0.0
Total gross tCO2e based on above

735.4
428.1
Intensity ratio: Tonnes of CO2/'000 patient appointments

1.86
1.27

Methodology                                                                                        Internal Methodology - Location Based (UK)
 
- 7 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
DIRECTOR'S REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024

Quantification and reporting methodology
We have followed the 2019 HM Government environmental reporting guidelines. We have also used the GHG reporting protocol – Corporate Standard and have used the 2021 UK Government's conversion factors for company reporting.
Intensity Measurement
The chosen intensity measurement ratio is total gross emissions in metric tonnes CO2e per ‘000 patient appointments.
Energy Efficiency Measures in the period
Energy use has been a focus across the company with new sites designed to high standards. Further improvements have been identified in our carbon reduction plan and investments have begun in energy metering and the introduction of battery operated mechanically propelled vehicles.
Looking ahead, we have several impactful projects planned that will further drive reductions, including the introduction of automatic route optimisation software, the adoption of electric fleet vehicles, and the establishment of regional stock hub-and-spoke models to streamline logistics. Additionally, the move to monthly collation of Scope 1, 2, and 3 emissions data will enable us to identify trends and address them proactively.
As we expand into 2025, opening further sites, our carbon footprint will therefore likely increase in the short to medium term. However implementing our carbon reduction plan with continued energy efficient investment focussing on embedding good engineering standards into new sites with LEDs, effective building controls, energy saving campaigns and efficient use of vehicles will result in a fall in our intensity ratio year on year whilst it takes several years for total emissions to see a significant decline.

Matters covered in the Strategic Report

Certain information not shown in the Directors' Report is shown in the Strategic Report on pages 1 - 5 instead in accordance with Section 414C(11) of the Companies Act 2006. This includes a business review, future developments and principal risks and uncertainties.

Disclosure of information to auditor

The director at the time when this Director's Report is approved has confirmed that:
 
so far as he is aware, there is no relevant audit information of which the Company's auditor is unaware, and

he has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Auditor

The auditor, Forvis Mazars LLPwill be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

- 8 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
DIRECTOR'S REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024

This report was approved by the board on 31 October 2024 and signed on its behalf.
 





I Rahman
Director

- 9 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF COMMUNITY HEALTH AND EYECARE LIMITED
 

Opinion

We have audited the financial statements of Community Health and Eyecare Limited (the ‘Company’) for the year ended 30 June 2024 which comprise the Statement of Comprehensive Income, the Statement of Financial Position, the Statement of Changes in Equity and notes to the financial statements, including a summary of significant accounting policies. 
The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

give a true and fair view of the state of the Company’s affairs as at 30 June 2024 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the "Auditor’s responsibilities for the audit of the financial statements" section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The director is responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
- 10 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF COMMUNITY HEALTH AND EYECARE LIMITED
 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:
 
the information given in the Strategic Report and the Director's Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the Strategic Report and the Director's Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Director's Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of director remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.

- 11 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF COMMUNITY HEALTH AND EYECARE LIMITED
 

Responsibilities of Director

As explained more fully in the Director's Responsibilities Statement set out on page 6, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the director is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director intends either to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
 
The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.
 
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. 

Based on our understanding of the Company and its industry, we considered that non-compliance with the following laws and regulations might have a material effect on the financial statements: employment regulation, health and safety regulation and anti-money laundering regulation.

To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks of material misstatement in respect to non-compliance, our procedures included, but were not limited to:
Inquiring of management and, where appropriate, those charged with governance, as to whether the company is in compliance with laws and regulations, and discussing their policies and procedures regarding compliance with laws and regulations;
Inspecting correspondence, if any, with relevant licensing or regulatory authorities;
Communicating identified laws and regulations to the engagement team and remaining alert to any indications of non-compliance throughout our audit; and
Considering the risk of acts by the company which were contrary to applicable laws and regulations, including fraud.  

We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such as: tax legislation, pension legislation and the Companies Act 2006. 
- 12 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF COMMUNITY HEALTH AND EYECARE LIMITED
 

In addition, we evaluated the director and management’s incentives and opportunities for fraudulent manipulation of the financial statements, including the risk of override of controls, and determined that the principal risks were related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates, revenue recognition (which we pinpointed to the cut-off assertion) and significant one-off or unusual transactions.

Our audit procedures in relation to fraud included but were not limited to:
Making enquiries of the directors and management on whether they had knowledge of any actual, suspected or alleged fraud;
Gaining an understanding of the internal controls established to mitigate risks related to fraud;
Discussing amongst the engagement team the risks of fraud; and
Addressing the risks of fraud through management override of controls by performing journal entry testing.

There are inherent limitations in the audit procedures described above and the primary responsibility for the prevention and detection of irregularities including fraud rests with management. As with any audit, there remained a risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal controls.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of the audit report

This report is made solely to the Company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body for our audit work, for this report, or for the opinions we have formed.




Christopher Martin (Senior Statutory Auditor)

  
for and on behalf of Forvis Mazars LLP

Chartered Accountants and Statutory Auditor 
One St. Peter's Square
Manchester
M2 3DE



31 October 2024
- 13 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2024

2024
2023
Note
£
£

  

Turnover
 4 
79,992,467
55,317,179

Cost of sales
  
(30,875,506)
(20,964,034)

Gross profit
  
49,116,961
34,353,145

Administrative expenses
  
(29,560,570)
(19,990,945)

Operating profit
 5 
19,556,391
14,362,200

Interest receivable and similar income
  
59,476
-

Interest payable and similar expenses
 10 
(448,776)
(183,765)

Profit before tax
  
19,167,091
14,178,435

Tax on profit
 11 
(3,675,396)
(2,274,910)

Profit for the financial year
  
15,491,695
11,903,525

There were no recognised gains and losses for 2024 or 2023 other than those included in the statement of comprehensive income.

There was no other comprehensive income for 2024 (2023: £NIL).

The notes on pages 18 to 33 form part of these financial statements.

- 14 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
REGISTERED NUMBER: 07296068

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2024

2024
2023
Note
£
£

  

Fixed assets
  

Tangible assets
 12 
32,268,360
19,614,137

Investments
 13 
4,342,451
4,342,451

  
36,610,811
23,956,588

Current assets
  

Inventories
 14 
1,311,861
951,806

Debtors: amounts falling due within one year
 15 
26,769,977
21,477,810

Cash at bank and in hand
 16 
3,110,379
1,658,855

  
31,192,217
24,088,471

Creditors: amounts falling due within one year
 17 
(13,521,468)
(9,924,066)

Net current assets
  
 
 
17,670,749
 
 
14,164,405

Total assets less current liabilities
  
54,281,560
38,120,993

  

Creditors: amounts falling due after more than one year
 18 
(2,813,886)
(1,960,869)

  
51,467,674
36,160,124

Provisions for liabilities
  

Deferred taxation
 20 
(1,312,898)
(1,660,543)

Other provisions
 21 
(360,750)
(197,250)

  
 
 
(1,673,648)
 
 
(1,857,793)

  

Net assets
  
49,794,026
34,302,331


Capital and reserves
  

Called up share capital 
 22 
202
202

Profit and loss account
 23 
49,793,824
34,302,129

  
49,794,026
34,302,331


- 15 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
REGISTERED NUMBER: 07296068
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 JUNE 2024

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 31 October 2024.


I Rahman
Director

The notes on pages 18 to 33 form part of these financial statements.

- 16 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2024


Called up share capital
Profit and loss account
Total equity

£
£
£


At 1 July 2022
202
22,398,604
22,398,806


Comprehensive income for the year

Profit for the year
-
11,903,525
11,903,525
Total comprehensive income for the year
-
11,903,525
11,903,525



At 1 July 2023
202
34,302,129
34,302,331


Comprehensive income for the year

Profit for the year
-
15,491,695
15,491,695
Total comprehensive income for the year
-
15,491,695
15,491,695


At 30 June 2024
202
49,793,824
49,794,026


The notes on pages 18 to 33 form part of these financial statements.

- 17 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

1.


General information

Community Health and Eyecare Limited (the “Company”) is a private company, limited by shares and registered in England and Wales, registered number 07296068. The registered office is 1-6 Star Building, Caxton Road, Fulwood, Preston, United Kingdom, PR2 9BS.
The principal activity of the Company is a provider of community ophthalmology services.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The Company's functional and presentational currency is GBP, rounded to the nearest £.

The following principal accounting policies have been applied:

 
2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
the requirements of Section 7 Statement of Cash Flows;
the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Oracle Vision Topco Limited as at 30 June 2024 and these financial statements may be obtained from 1-6 Star Building, Caxton Road, Fulwood, Preston, PR2 9BS.

- 18 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)

 
2.3

Going concern

As at 30 June 2024, the Company had net assets of £49.8m (2023: £34.3m) including a bank cash balance of £3.1m (2023: £1.7m). In determining whether the Company’s accounts can be prepared on a going concern basis, the director considers the Company’s business activities together with factors likely to affect future development, performance, it’s financial position including cash flows, liquidity position, borrowing facilities and risks and uncertainties relating to its business activities.
This includes the director regularly reviewing these factors, and the performance and financial position of the wider group to ensure that any risks are recognised and managed effectively.
After considering all these factors the directors have a reasonable expectation that the Company, and wider Group, have adequate resources to continue in operation and manage the risks for the foreseeable future.  Accordingly, the director decided to adopt the going concern basis in the preparation of the annual financial statements.

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.6

Interest income

Interest income is recognised in profit or loss using the effective interest method.

- 19 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)

 
2.7

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.8

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.9

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

 
2.10

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

- 20 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)


2.10
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on the following bases.

Depreciation is provided on the following basis:

Leasehold improvements
-
Straight Line over length of lease (to break clause)
Plant & machinery
-
Straight line over 5 years
Motor vehicles
-
Straight line over 4 years
Fixtures & fittings
-
Straight line over 5 years
Computer equipment
-
Straight line over 3 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.11

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

  
2.12

Inventories

Inventories are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. 
At each reporting date, inventories are assessed for impairment. If inventories are impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.13

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.14

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.15

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

- 21 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)

 
2.16

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.17

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

The Company has elected to apply the recognition and measurement provisions of IFRS 9 Financial Instruments (as adopted by the UK Endorsement Board) with the disclosure requirements of Sections 11 and 12 and the other presentation requirements of FRS 102.

Financial instruments are recognised in the Company's Statement of Financial Position when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at each reporting date. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.
 
- 22 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)


2.17
Financial instruments (continued)

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Derecognition of financial instruments

Derecognition of financial assets

Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.

- 23 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

3.


Judgments in applying accounting policies and key sources of estimation uncertainty

In the application of the Company’s accounting policies, the director is required to make judgments, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.
Useful economic lives of tangible fixed assets
The annual depreciation charge for tangible fixed assets is sensitive to changes in the estimated economic lives and residual values of assets. the useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates.
 

4.


Turnover

An analysis of turnover by class of business is as follows:


2024
2023
£
£

Health Care Services
79,992,467
55,317,179


All turnover arose within the United Kingdom.


5.


Operating profit

The operating profit is stated after charging/(crediting):

2024
2023
£
£

Depreciation of tangible fixed assets
6,911,567
3,868,603

Operating lease charges
2,651,756
1,841,599

Defined contribution pension cost
247,848
156,809

Profit on sale of assets
(3,325)
-

- 24 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

6.


Auditor's remuneration

During the year, the Company obtained the following services from the Company's auditor:


2024
2023
£
£

Fees payable to the Company's auditor for the audit of the Company's financial statements

60,000
54,000

Fees payable to the Company's auditor in respect of:

Taxation compliance services
2,770
2,500

All non-audit services not included above
3,180
3,100


7.


Employees

Staff costs, including director's remuneration, were as follows:


2024
2023
£
£

Wages and salaries
17,818,215
11,664,029

Social security costs
1,744,347
1,155,752

Cost of defined contribution scheme
247,848
156,809

19,810,410
12,976,590


The average monthly number of employees, including the director, during the year was as follows:


        2024
        2023
            No.
            No.







Administrative
148
88



Operations
101
97



Doctors and Technicians
270
174

519
359

The prior year employee numbers have been updated to correctly reflect the average monthly number of employees in the year. 

- 25 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

8.


Director's remuneration

2024
2023
£
£

Director's emoluments
189,000
179,161

Company contributions to defined contribution pension schemes
1,321
1,321

190,321
180,482


During the year retirement benefits were accruing to 1 director (2023 - 1) in respect of defined contribution pension schemes.


9.


Interest receivable

2024
2023
£
£


Other interest receivable
59,476
-


10.


Interest payable and similar expenses

2024
2023
£
£


Finance leases and hire purchase contracts
447,886
180,901

Other interest payable
890
2,864

448,776
183,765

- 26 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

11.


Taxation


2024
2023
£
£

Corporation tax


Current tax on profits for the year
4,742,708
2,339,811

Adjustments in respect of previous periods
(719,667)
(616,072)


Total current tax
4,023,041
1,723,739

Deferred tax


Origination and reversal of timing differences
(347,785)
422,399

Adjustments in respect of previous periods
140
128,772

Total deferred tax
(347,645)
551,171


Taxation on profit on ordinary activities
3,675,396
2,274,910

Factors affecting tax charge for the year

The tax assessed for the year is lower than (2023 - lower than) the standard rate of corporation tax in the UK of 25% (2023 - 20.5%). The differences are explained below:

2024
2023
£
£


Profit on ordinary activities before tax
19,167,091
14,178,435


Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2023 - 20.5%)
4,791,773
2,906,579

Effects of:


Fixed asset differences
62,972
64,100

Expenses not deductible for tax purposes
11,844
15,631

Adjustments to tax charge in respect of prior periods
(719,667)
(616,072)

Adjustments to tax charge in respect of previous periods - deferred tax
140
128,772

Remeasurement of deferred tax for changes in tax rates
-
76,102

Income not taxable for tax purposes
(53,726)
-

Other tax adjustments, reliefs and transfers
(1,768)
285

Group relief claimed
(416,172)
(300,487)

Total tax charge for the year
3,675,396
2,274,910

- 27 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
 
11.Taxation (continued)


Factors that may affect future tax charges

There were no factors that may affect future tax charges.


12.


Tangible fixed assets





Leasehold improvements
Plant & machinery
Motor vehicles
Fixtures & fittings
Computer equipment
Total

£
£
£
£
£
£



Cost


At 1 July 2023
14,764,445
10,294,554
359,729
600,268
1,649,365
27,668,361


Additions
10,734,560
8,602,475
-
306,784
633,323
20,277,142


Disposals
(317,415)
(343,543)
-
(4,532)
(254,584)
(920,074)


Transfers between classes
355,999
(355,999)
-
-
-
-



At 30 June 2024

25,537,589
18,197,487
359,729
902,520
2,028,104
47,025,429



Depreciation


At 1 July 2023
3,916,120
3,091,600
121,016
229,345
696,143
8,054,224


Charge for the year
3,651,162
2,463,922
89,992
135,497
570,229
6,910,802


Disposals
(11,902)
(167,142)
-
(87)
(28,826)
(207,957)


Transfers between classes
94,933
(94,933)
-
-
-
-



At 30 June 2024

7,650,313
5,293,447
211,008
364,755
1,237,546
14,757,069



Net book value



At 30 June 2024
17,887,276
12,904,040
148,721
537,765
790,558
32,268,360



At 30 June 2023
10,848,325
7,202,954
238,713
370,923
953,222
19,614,137

The net book value of assets held under finance leases or hire purchase contracts, included above, are as follows:


2024
2023
£
£



Plant and machinery
7,700,140
3,447,060

- 28 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

13.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 July 2023
4,342,451



At 30 June 2024
4,342,451





Subsidiary undertaking


The following was a subsidiary undertaking of the Company:

Name

Registered office

Class of shares

Holding

Academy of Health Experts Limited
1-6 Star Building Caxton Road, Preston, PR2 9BS
Ordinary
100%


14.


Inventories

2024
2023
£
£

Finished goods and goods for resale
1,311,861
951,806


- 29 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

15.


Debtors

2024
2023
£
£


Trade debtors
4,352,027
5,999,414

Amounts owed by group undertakings
8,286,800
4,798,142

Other debtors
278,707
85,315

Prepayments and accrued income
12,126,243
9,396,105

Tax recoverable
1,726,200
1,198,834

26,769,977
21,477,810


Amounts owed by group undertakings are unsecured, interest free and repayable on demand. 


16.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
3,110,379
1,658,855



17.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
2,457,192
3,689,956

Amounts owed to group undertakings
1,684,160
1,764,554

Other taxation and social security
523,538
424,297

Obligations under finance lease and hire purchase contracts
3,746,901
1,692,344

Other creditors
1,427,653
525,460

Accruals and deferred income
3,682,024
1,827,455

13,521,468
9,924,066


Amounts owed to group undertakings are unsecured, interest free and repayable on demand. 
Net obligations under hire purchase contracts and finance leases are secured by fixed charges on the assets concerned.

- 30 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

18.


Creditors: Amounts falling due after more than one year

2024
2023
£
£

Net obligations under finance leases and hire purchase contracts
2,813,886
1,960,869


Net obligations under hire purchase contracts and finance leases are secured by fixed charges on the assets concerned.


19.


Hire purchase and finance leases


Minimum lease payments under hire purchase fall due as follows:

2024
2023
£
£


Within one year
3,746,901
1,675,716

In two to five years
2,813,886
1,960,869

6,560,787
3,636,585

Finance lease payments represent rentals payable by the Company for certain items of plant and machinery. Leases include purchase options at the end of the lease period, and no restrictions are placed on the use of the assets. The average lease term is 5 years. All leases are on a fixed repayment basis and no arrangements have been entered into for contingent rental payments.


20.


Deferred taxation




2024
2023


£

£






At beginning of year
(1,660,543)
(1,109,372)


Charged to profit or loss
347,645
(551,171)



At end of year
(1,312,898)
(1,660,543)

- 31 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
 
20.Deferred taxation (continued)

The provision for deferred taxation is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(1,479,316)
(1,776,181)

Short term timing differences
166,418
115,638

(1,312,898)
(1,660,543)


21.


Provisions




Dilapidation provision

£





At 1 July 2023
197,250


Charged to profit or loss
163,500



At 30 June 2024
360,750


22.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



96 (2023 - 96) Ordinary A shares of £1.00 each
96
96
6 (2023 - 6) Ordinary B shares of £1.00 each
6
6
100 (2023 - 100) Ordinary C shares of £1.00 each
100
100

202

202


Ordinary A, B and C shares have attached to them full voting and dividend rights. They do not confer any rights of redemption.
On return of capital, whether on liquidation, capital reduction or otherwise (including on winding up), any surplus assets of the company remaining after the payment of its liabilities are first applied to the holders of the A Ordinary and B Ordinary shares up to £3,154,818. The balance of any surplus assets are then to be distributed to the holders of the C Ordinary and B Ordinary shares. Distributions of surplus assets between classes of shares are pro rata according to the number of shares of the relevant class held by each of them respectively. 

- 32 -

 
COMMUNITY HEALTH AND EYECARE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

23.


Reserves

Profit & loss account

The profit and loss account reserve represents cumulative profits and losses.


24.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £247,848 (2023 - £156,809). Contributions totalling £54,923 (2023 - £35,703) were payable to the fund at the reporting date and are included in creditors.


25.


Commitments under operating leases

At 30 June 2024 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2024
2023
£
£


Not later than 1 year
1,965,200
1,593,622

Later than 1 year and not later than 5 years
6,106,820
4,164,177

Later than 5 years
646,533
-

8,718,553
5,757,799


26.


Related party transactions

The Company is a wholly owned subsidiary of Oracle Vision Topco Limited and has taken advantage of the exemption in Section 33 of Financial Reporting Standard 102 (Related Party Disclosures) from the requirement to disclose transactions with other wholly owned group companies.


27.


Controlling party

The ultimate parent company is Oracle Vision Topco Limited, a company registered in England and Wales. The immediate parent company is Community Health & Eyecare (Holdings) Ltd, a company registered in England and Wales.
The ultimate controlling party is I Rahman.
The Company is consolidated within Oracle Vision Topco Limited group financial statements and copies can be obtained upon request from the group's registered office, 1-6 Star Building, Caxton Road, Fulwood, Preston, PR2 9BS.

- 33 -